|
A WEEK-IN-REVIEW FEATURED REPORT
CONFERENCE PDF POSTER 
New Tablet Formulation of Lopinavir/Ritonavir
Bioequivalent to the Capsule at a Dose of 800/200
T. Zhu, Y. Chiu, T. Doan, et al
Conference Poster
|
A WEEK-IN-REVIEW FEATURED REPORT
CONFERENCE PDF POSTER
Differences in
Treatment Compliance Between Lopinavir/ritonavir (LPV/r) Given Once
(QD) Versus
Twice (BID) Daily Do Not Affect Virologic or Immunologic Outcomes
R. Rode, B. Vrijens, K. Niemi , et al
Conference Poster
|
A WEEK-IN-REVIEW FEATURED REPORT
CONFERENCE PDF
POSTER
Comparative Safety and Anti-HIV Activity of a Dual Protease
Inhibitor Regimen (Lopinavir/ritonavir+
Saquinavir) versus a Nucleoside-Containing Regimen
DW. Cameron, J. Eron, C. Farthing, et al
Conference Poster
Plasma HDL Cholesterol Increases as a Function of
Long-Term Exposure to Lopinavir/Ritonavir
(LPV/r), in Naive and Pre-Treated HIV-Infected Patients
J. MEYNARD, K. LACOMBE , J. POIRIER, et al
Conference Abstract
Rapid Emergence of Resistance to Lopinavir in HIV-2 Due to Selection of
ProV47A Mutation
B. RODES, C. TORO, J. SHELDON, V. JIMENEZ, et al
Conference Abstract |
|
|
|